u 135 white oval pill

U 135 white oval pill

If you are a consumer or patient please visit this version. Clonidine hydrochloride, USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.

If you are a consumer or patient please visit this version. History of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, angioedema. Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder ADHD as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies 14 ]. Clonidine hydrochloride extended-release tablets are an extended-release tablet to be taken orally with or without food.

U 135 white oval pill

.

No adequate, well-controlled studies have been conducted in pregnant women. Ophthalmological: Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of eyes. Studies have indicated that 2.

.

It is advised to take this medication orally as directed by your doctor. The dosage will depend on the condition and your response to the treatment. Follow the instructions given by the doctor, dosage will be decided by the doctor according to your condition and response to the treatment. If any of these side effects last more than 2 days or cause any problems. Then you should consult your doctor. It is advised to store u pill in the airtight container that comes with it.

U 135 white oval pill

Go PRO to access past versions. Teratogenic Effects: Pregnancy Category C Reproduction studies performed in rabbits at doses up to approximately 3 times the oral maximum recommended daily human dose MRDHD of clonidine hydrochloride tablets produced no evidence of a teratogenic or embryotoxic potential in rabbits. Increased resorptions were not associated with treatment at the same time or at higher dose levels up to 3 times the oral MRDHD when the dams were treated on gestation days 6 to No adequate, well-controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. As clonidine hydrochloride is excreted in human milk, caution should be exercised when clonidine hydrochloride tablets are administered to a nursing woman. Go PRO for all pill images.

Planisphère continent vierge

Clonidine stimulates alpha-adrenoreceptors in the brain stem. Also advise patients to avoid the use of clonidine hydrochloride extended-release tablets with other centrally active depressants and with alcohol [see Warnings and Precautions 5. Your doctor may prescribe clonidine hydrochloride extended-release tablets alone or together with certain other ADHD medicines. Instruct patients to use caution when driving a car or operating hazardous machinery until they know how they will respond to treatment with clonidine hydrochloride extended-release tablets. Based on observations in patients in a state of alcoholic delirium it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential QT- prolongation, ventricular fibrillation of high intravenous doses of haloperidol. Initial Dose 0. Ask your doctor or pharmacist for a list of these medicines, if you are not sure if your medicine is listed above. Before you take clonidine hydrochloride extended-release tablets, tell your doctor if you: have kidney problems have low or high blood pressure have a history of passing out syncope have heart problems, including history of heart attack have had a stroke or have stroke symptoms had a skin reaction such as a rash after taking clonidine in a transdermal form skin patch have any other medical conditions are pregnant or plan to become pregnant. Studies have indicated that 2. You may need a different medicine. The likelihood of such reactions to discontinuation of clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant beta-blocker treatment and special caution is therefore advised in these situations. General information about the safe and effective use of clonidine hydrochloride extended-release tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

Learn about the medical, dental, pharmacy, behavioral, and voluntary benefits your employer may offer. Use only as directed.

Clonidine acutely stimulates growth hormone release in both children and adults, but does not produce a chronic elevation of growth hormone with long-term use. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine hydrochloride extended-release tablets following dialysis. Inactive Ingredients. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage , we no longer display the RxImage pill images associated with drug labels. Keep a list of your medicines with you to show your doctor and pharmacist when you get a new medicine. Clonidine is a known antihypertensive agent. Do not take more than the prescribed total daily amount of clonidine hydrochloride extended-release tablets in any hour period. The inactive ingredients are colloidal silicon dioxide, corn starch, dibasic calcium phosphate, sodium starch glycolate, glycerin, lactose monohydrate, magnesium stearate, povidone. Labeler - Lupin Pharmaceuticals, Inc. No adequate, well-controlled studies have been conducted in pregnant women. The following adverse reactions have been identified during post-approval use of clonidine hydrochloride extended-release tablets. Genitourinary: Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, nocturia, and urinary retention. NDC 1 2 3 DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.

2 thoughts on “U 135 white oval pill

Leave a Reply

Your email address will not be published. Required fields are marked *